Second quarter 2023 results
Second quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
14:30 -16:00 CET | 8:30am – 10am EST
Featuring
![Paul Hudson](/optim/dotcom/test/images/events/paul-hudson-featuring_20230405202911.jpg?size=small)
Paul Hudson
Chief Executive Officer
![Jean-Baptiste de Chatillon](/optim/dotcom/test/images/events/jb-dechatillon-featuring_20230405202911.png?size=small)
Jean-Baptiste de Chatillon
Chief Financial Officer
![Bill Sibold](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/BillSibold_20230417070309.png?size=small)
Bill Sibold
Specialty Care
![Olivier Charmeil](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/OlivierCharmeil_20230417070553.png?size=small)
Olivier Charmeil
General Medicines
![Dietmar Berger](/optim/dotcom/content-app/events/quaterly-results/2023/q1-2023/Dietmar-Berger_20230427085455.png?size=small)
Dietmar Berger
Global Head of R&D ad interim
![Thomas Triomphe](/optim/dotcom/content-app/events/quaterly-results/2022/q4-results-2022/ThomasTriomphe_20230417070802.png?size=small)
Thomas Triomphe
Vaccines
![Julie van Ongevalle](/optim/dotcom/content-app/biographies/bio-julie-van-ongevalle_20231207083600.jpg?size=small)
Julie van Ongevalle
Consumer Healthcare
![Roy Papatheodorou](/optim/dotcom/content-app/biographies/bio-roy-papatheodorou_20240329142328.jpg?size=small)
Roy Papatheodorou
General Counsel
Highlights
![](/optim/dotcom/content-app/events/quaterly-results/2023/2023-q2-2023-results/thumbnail-youtube-paul-hudson-min.jpg?size=large)
We delivered another solid quarter of growth and are excited by the momentum of our R&D pipeline, with a strong flow of positive readouts and regulatory achievements that match our best-in-class ambitions.
![Paul Hudson](/optim/dotcom/content-app/biographies/bio-paul-hudson.jpg?size=small)
Paul Hudson
Chief Executive Officer